Xvivo Perfusion AB 2023 AR2
The report highlights XVIVO's strongest financial year to date in 2023, achieving total sales of SEK 598 million with 30 percent organic growth. The company advanced its clinical trials, completing patient inclusion for its European heart preservation study and initiating a US clinical trial. XVIVO also expanded its service offering in the US by integrating STAR Teams and partnering with MTJ Aviation to optimize organ recovery logistics. In sustainability, the company focused on ethical business, employee commitment, and high-quality products, with 79 percent of its global power supply derived from renewable energy sources.
Company: Xvivo Perfusion AB
Sector: Health Care
Country: Sweden
Year: 2023
Type: AR2
Pages: 127
Xvivo Perfusion AB
Annual Report
The report highlights XVIVO's strongest financial year to date in 2023, achieving total sales of SEK 598 million with 30 percent organic growth. The company advanced its clinical trials, completing patient inclusion for its European heart preservation study and initiating a US clinical trial. XVIVO also expanded its service offering in the US by integrating STAR Teams and partnering with MTJ Aviation to optimize organ recovery logistics. In sustainability, the company focused on ethical business, employee commitment, and high-quality products, with 79 percent of its global power supply derived from renewable energy sources.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Women in Management
Workplace Fatalities
Employees